

### Research Day

March 14, 2024 | 1:00 pm — 5:00 pm Apotex Building — Bannatyne Campus

Recognizing accomplishments in research and innovation in the College of Pharmacy, University of Manitoba.



### **PROGRAM**

**1:00 pm** Welcome Address by the Dean and Chair

Dr. Lalitha Raman-Wilms

Dr. Kaarina Kowalec 050 Apotex Centre

1:15 pm Dr. Daniel Mueller, University of Toronto

"Clinical Application of Pharmacogenomics in Psychiatry"

Invited speaker (45 min present + 15 min Q&A)

050 Apotex Centre

**2:15 pm** Dr. Anna Chudyk, University of Manitoba

"Patient engagement in research: contexts, applications, and future

Directions"

Faculty speaker (45 min present + 15 min Q&A)

050 Apotex Centre

**3:15 pm** Poster Session

3rd floor atrium—Apotex Centre

**4:15 pm** BREAK

Judges select poster winner

**4:30 pm** Poster Award, Closing remarks

Dr. Kaarina Kowalec

3rd floor atrium—Apotex Centre



### **KEYNOTE SPEAKER**

## Clinical Application of Pharmacogenomics in Psychiatry

Thursday, March 14, 2024 | 1:15 pm - 2:15 pm

050 Apotex Building | Bannatyne Campus | University of Manitoba



Speaker: Daniel Mueller, MSc, MD, PhD, MHS
Professor, University of Toronto

Dr. Daniel Mueller is a Professor at the Department of Psychiatry at the University of Toronto and a Senior Scientist at the Centre for Addiction and Mental Health. He is Head of the Pharmacogenetics Research Clinic at CAMH where he developed the first pharmacogenetic testing service for patients with psychiatric conditions in Canada.

Dr. Mueller's overarching research goal is to advance precision medicine using genomics and computer sciences. He has published over 300 peer-reviewed articles and received international recognitions for his innovative research and implementation strategies on pharmacogenetics.

Dr. Mueller is President of the Canadian College of Neuropsychopharmacology and member of the Clinical Pharmacogenetics Implementation Consortium where he contributed to pharmacogenetic implementation guidelines for antidepressants, opioids, atomoxetine, and mood stabilizers.



#### **FACULTY PROGRAM**

# Patient engagement in research: contexts, applications, and future directions

Thursday, March 14, 2024 | 2:15 pm - 3:15 pm

050 Apotex Building | Bannatyne Campus | University of Manitoba



Speaker: Anna M. Chudyk, MSc, PhD
Assistant Professor, College of Pharmacy, University of Manitoba

Dr. Anna Chudyk obtained Bachelors of Health Sciences and Masters of Epidemiology and Biostatistics degrees from the University of Western Ontario and a Doctorate in Experimental Medicine from the University of British Columbia. Her research career is marked by prestigious National level awards and recognitions, including a Charles Best Canada Graduate Scholarship, a Vanier Canada Graduate Scholarship, and most recently Phase 1 and 2 Patient-Oriented Research Awards - Transition to Leadership Stream Fellowships, all from the Canadian Institutes of Health Research.

Dr. Chudyk's presentation will:

- Provide an overview of the contexts underlying patient engagement in research
- Identify key considerations for engaging patients in research
- Describe applications of key individual and systems level future directions for patient engagement in research



### **POSTERS**

POSTER#	Poster Title	Name
#1	Prenatal Exposure to Gabapentin and the Risk of Autism Spectrum Disorder in Children	Akinola, Samuel <i>MSc. student</i>
#2		Aziz, Md Abdul PhD. student
#3	Omega-3 fatty acids modify monocyte glucose metabolism through mito- chondrial bioenergetic rewiring	Byun, Michael <i>MSc. student</i>
#4		Das, Urmi Post-doc Fellow
#5		Esteban Villarba, Jenna <i>MSc. student</i>
#6		Farooq, Faiza PhD. student
#7	The role of Pref-1 in non-inflammatory insulin resistance	Huang, Yiheng PhD. student
#8	A kinetic study of DOT1L with mass spectroscopy	lge, Olufola PhD. student
#9		Kantroo, Meher PhD. student
#10	Gabapentin Use During Pregnancy and Adverse Neonatal Birth Outcomes: A Canadian multi-site Population-Based Cohort Study	Lavu, Alekhya PhD. student
#11	Neutralizing interleukin (IL)-1β reduces formation of islet amyloid polypeptide aggregates in human islets during ex vivo culture	Malhotra, Danish <i>MSc. student</i>
#12		Safa, Mira <i>MSc. student</i>
#13	Treatment with a glucagon-like peptide-1 agonist reduces formation of toxic islet amyloid polypeptide oligomers and improves beta-cell survival in human islets during pre-transplant culture	
#14		Shirinbakhshmasoleh, Mina <i>MSc. student</i>
#15	The effects of elevated glucose on islet-derived extracellular vesicles – Implication in type 2 diabetes	Tyagi, Rushie <i>MSc. student</i>
#16	Evaluating Covalent Engagement of Boron-Modified Topoisomerase I Inhibitors as Chemotherapeutic Agents	Vuong, Billy PhD. student